 |
|
|
| |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults
With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I)
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 san Francisco, CA
Tarik Asselah1, Tarek I Hassanein2, Roula B Qaqish3, Jordan J Feld4, Christophe Hezode5, Stefan Zeuzem6, Peter Ferenci7, Tami Pilot-Mati as3, Yao Yu3, Rebecca Redman3, Niloufar Mobashery3
1Centre de Recherche sur l'Infl ammati on, Inserm UMR 1149, Universite Paris Diderot, AP-HP Hopital Beaujon, Clichy, France; 2Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States;
4Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 5Henri Mondor University Hospital, AP-HP, Universite Paris-Est, Creteil, France; 6JW Goethe University, Frankfurt, Germany; 7Medical University Vienna, Vienna, Austria
|
| |
|
|
|
|
|
